CAR-T vs bispecific antibodies for lymphoma

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, Laurie Sehn, MD, BC Cancer Agency, Prince George, BC, Canada, and David Maloney, MD, PhD, Fred Hutchinson Cancer Research Centre, Seattle, WA, discuss immunotherapies at the 17th International Workshop on Non-Hodgkin Lymphoma held in Boston, MA. They debate the success of bispecific antibodies compared with CAR T-cells, and highlight differences including cost, toxicity profiles and target antigen availability. In addition, they discuss the possibility of moving these new therapies forwards in the treatment pathway.